DF-003(Drug Farm)
- Generic Name
- DF-003(Drug Farm)
Phase 3 Trial Shows Promising Results for Novel Encapsulated Cell Therapy in MacTel Treatment
• Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.
• The innovative implantable device, developed by Neurotech, maintains long-term viability with CNTF production documented for up to 14.5 years, offering a potential alternative to frequent intravitreal injections.
• FDA review of the therapy is currently underway with a PDUFA date set for March 18, 2025, marking a potential breakthrough in MacTel treatment.
Drug Farm Partners with NIH to Develop Treatment for ROSAH Syndrome
Drug Farm has entered into a Cooperative Research and Development Agreement with the NIH's NIAID to develop DF-003, a precision targeted drug for ROSAH syndrome, marking a significant step towards providing therapeutic benefits for patients with this rare genetic disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath